The increasing resistance of the malaria parasite Plasmodium falciparum to currently available drugs demands a continuous effort to develop new antimalarial agents. In this quest, the identification of antimalarial effects of drugs already in use for other therapies represents an attractive approach with potentially rapid clinical application. We have found that the extensively used antimycotic drug clotrimazole (CLT) effectively and rapidly inhibited parasite growth in five different strains of P. falciparum, in vitro, irrespective of their chloroquine sensitivity. The concentrations for 50% inhibition (IC50), assessed by parasite incorporation of [ 3 H]hypoxanthine, were between 0.2 and 1.1 M. CLT concentrations of 2 M and above caused a sharp decline in parasitemia, complete inhibition of parasite replication, and destruction of parasites and host cells within a single intraerythrocytic asexual cycle (Ϸ48 hr). These concentrations are within the plasma levels known to be attained in humans after oral administration of the drug. The effects were associated with distinct morphological changes. Transient exposure of ring-stage parasites to 2.5 M CLT for a period of 12 hr caused a delay in development in a fraction of parasites that reverted to normal after drug removal; 24-hr exposure to the same concentration caused total destruction of parasites and parasitized cells. Chloroquine antagonized the effects of CLT whereas mefloquine was synergistic. The present study suggests that CLT holds much promise as an antimalarial agent and that it is suitable for a clinical study in P. falciparum malaria.
I
n the course of an investigation on the homeostasis of human red cells infected in vitro with the human malaria parasite Plasmodium falciparum, we found that clotrimazole (CLT), an imidazole derivative used as an antifungal agent (1), had a powerful growth-inhibiting effect on the parasite. The vast clinical experience, proven tolerance, and unique lack of acquired fungal resistance to CLT prompted a detailed investigation of its antimalarial effects in cultures of P. falciparum to assess its clinical potential. In this study, we report the in vitro effects of CLT on P. falciparum cultures by assessing the timeand concentration-dependent changes in parasite growth, parasite morphology, stage-specific development, and parasite replication.
Materials and Methods
Cultures. Five different laboratory strains of P. falciparum [A4 (2), W2, NF54, HB3, and FCR] were cultured in human erythrocytes by standard methods (3) under a low oxygen atmosphere. The culture medium was RPMI 1640, supplemented with 40 mM Hepes, 25 mg͞liter gentamicin sulfate, 10 mM D-glucose, 2 mM glutamine, and either 8.5% (vol͞vol) pooled human serum (A4 clone), or 10% heat-inactivated plasma (strains W2, NF54, HB3, and FCR). Culture media, with or without CLT, were changed daily, unless otherwise indicated. Parasites were synchronized at the ring stage with D-sorbitol (4) for all experiments. Initial parasitemias varied between 2% and 7% for the different experiments.
Assessment of Parasite Morphology, Stage-Specific Development, and
Replication. Parasite morphology, stage-specific development, and replication were evaluated in cultures by microscopic inspection of Giemsa-stained thin blood smears. Smears from drug-free cultures were always used as controls. Stage-specific development was assessed by examining a minimum of 600 parasitized cells on each smear, for differential counting of rings, trophozoites, schizonts, and pyknotic forms whose developmental stage could not be established. The fraction of each group was calculated as a percentage of the total parasitized cells. Parasitemia was measured by counting 2,000 red cells and is reported as the percent of parasitized erythrocytes. Morphologically normal and abnormal parasites were included in the measurements. Parasite replication was evaluated from successive parasitemia measurements at the beginning of each new asexual cycle.
Growth Inhibition Assay. P. falciparum growth was assessed by measuring the incorporation of the radiolabeled nucleic acid precursor [ 3 H]hypoxanthine (5) in media containing either human pooled serum or heat-inactivated plasma. All assays were started with ring stage-synchronized cultures at 2-4% parasitemia and processed as reported (6) (7) (8) . Aliquots of stock solutions of CLT in DMSO were placed in the wells of flatbottomed cell culture plates (Nunc), under sterile conditions, to render final concentrations of 0.1-5 M CLT after the addition of either control or parasitized red cell suspensions in culture medium. DMSO concentrations did not exceed 0.2% (vol͞vol) in cultures. The plates were placed in a gas-tight box that was flushed with a low oxygen gas mixture, sealed, and incubated at 37°C for about 16-20 hr. [ 3 H]Hypoxanthine in culture medium (5-25 Ci͞ml, final concentration) then was added to each well (10% vol͞vol) and after a further 18-to 24-hr incubation, the cells were harvested and the cell-associated radioactivity was measured by scintillation counting. For the assessment of parasite growth in younger ring-stage parasites of clone A4, [ 3 H]hypoxanthine was added 15 min after parasite exposure to CLT and the incorporation period was 20 hr. Suspensions of uninfected erythrocytes similarly treated were used for background subtraction. Parasite morphology was determined by Giemsa-stain smears immediately before the start of [ Hall Institute, Melbourne, Australia, to H.G.). H]Hypoxanthine was from Amersham Life Sciences. A stock solution of CLT (25 mM) was prepared in DMSO and further diluted in DMSO or culture medium as needed. These concentrations had no effect on parasite growth when tested in control cultures. Stock solutions of chloroquine were prepared in distilled water. Mefloquine was dissolved in ethanol and final dilutions were made in complete culture medium. (Table 1) .
Results

CLT
CLT Alters P. falciparum Morphology and Interferes with Parasite
Development and Replication. The effects of CLT on parasite morphology, development, and replication were evaluated in synchronized cultures of three strains of P. falciparum (A4, NF54, and W2). The effects were similar in all strains, at CLT concentrations characteristic for each strain (Table 1) . Figs. 2-4 illustrate the effects observed in clone A4. CLT caused a marked decline in parasitemia at concentrations of 2 M and above ( Fig.  2) . At these concentrations, there was complete inhibition of parasite replication as well as degeneration and destruction of parasites and their host cells, within a single asexual cycle. The effect on parasitemia was evident after 48-hr incubation when there was a sharp concentration-dependent transition between 1 and 2 M CLT (Fig. 2) . Lower concentrations of CLT (0.5 and 1 M) caused a mild decrease in parasitemia relative to controls that was apparent only at 72 and 96 hr.
CLT inhibited parasite development and altered normal morphology in all strains (Fig. 3 ). Pyknosis and vacuolation were the most prominent morphological changes. Fig. 4 shows the effects of CLT on parasite development (A4 clone). After 24-hr incu- bation, most parasites exposed to CLT concentrations above 2 M were morphologically abnormal, more than half were shrunk, reduced to a pyknotic mass, and a significant fraction (17%) failed to develop beyond the ring-trophozoite stage (Figs. 3 and 4). After 48 hr, only pyknotic forms were present (Fig. 4) . Incubation with 2 M CLT showed that by 24 hr most parasites had developed from ring forms to more mature trophozoites except for a fraction of rings (10%) that showed delayed or arrested development. However, the trophozoites were smaller than controls and morphologically abnormal. Most of them failed to develop to schizonts, indicating that development was arrested mainly at mid-trophozoite stage. The effects with 2 M CLT were more dramatic by 48 hr postincubation, by which time most parasites were markedly pyknotic; there was no progression to a second asexual cycle. Lower CLT concentrations (0.5 and 1 M) caused only a slight but consistent retardation of parasite development.
Effects of Transient in Vitro Exposure of P. falciparum to CLT. The effects of transient in vitro exposure to CLT were investigated in synchronized cultures (A4 clone) to assess the potential effectiveness of short-term treatments. Ring-stage and late trophozoite-stage cultures were exposed for 12 hr to both 1.5 and 2.5 M CLT after which the cells were washed and cultured in drug-free media. Parasitemia and stage-specific development were assessed before and after 12-hr incubation, thereafter, every 24 hr, for a total of 72 hr (trophozoites) or 96 hr (rings), and compared with drug-free controls. Ring trophozoites were not susceptible to a 12-hr exposure to CLT concentrations of 1.5 and 2.5 M. The only documented abnormality was a transient delay in development in a fraction of parasites which remained in the ring stage (R) (controls: 28% R; 1.5 M CLT: 50% R; 2.5 M: 73% R). Normal development resumed after the cells were washed and incubated in a drug-free medium. By contrast, late trophozoite-stage parasites were susceptible to 12-hr treatment with 2.5 M CLT (there was no effect with 1.5 M). After 12-hr incubation, coincident with the beginning of the second parasite asexual cycle, there was a large proportion (Ϸ30%) of pyknotic forms that did not appear to recover after removal of the drug; a significant fraction of schizonts were slightly shrunken. In the second asexual cycle, parasitemia was 70% lower than in controls, indicating a marked inhibition of parasite replication. Nevertheless, normal development resumed after removal of CLT, as shown by the increase in parasitemia in the subsequent cycle. These results suggest that the effect of CLT on ring trophozoites is cytostatic rather than cytotoxic, and that the cytotoxic effect is cumulative with time.
A longer incubation period of 24 hr with 2.5 M CLT was tested in synchronized ring-stage parasites (A4 clone). After 24-hr incubation, CLT was removed and the incubation continued for a further 96 hr. No parasites could be found in culture at 72 hr or later, indicating parasite death and disintegration of the infected cells. Combined Effects of CLT with Other Antimalarials. Combinations of CLT with mefloquine or chloroquine were tested against a P. falciparum chloroquine-sensitive (HB3) strain and a chloroquine-resistant (W2) strain. Isobole analysis (9) of the results with strain HB3 (Fig. 5 ) demonstrated a substantial antagonism between CLT and chloroquine and a significant synergy between CLT and mefloquine. CLT antagonism with chloroquine also was obtained with strain W2; however, in this strain, the data on the interaction of CLT with mefloquine were inconclusive.
Discussion
This study demonstrates a potent antimalarial effect of CLT on five different strains of P. falciparum in vitro. CLT had time-and concentration-dependent effects with a broad stage specificity of action. However, the drug was more effective at the latetrophozoite and schizont stages than at the ring-trophozoite stage. Parasite growth was inhibited with an IC 50 Ϸ1 M, as assessed both morphologically and by the incorporation of [ 3 H]hypoxanthine. The transient effects observed after a 12-hr exposure of ring forms to 2.5 M CLT suggest that at this concentration CLT has a cytostatic effect on younger asexual stages. For cytotoxic effects to develop, a longer parasite exposure to the drug is necessary. The total disappearance of parasites and disintegration of parasitized cells observed after a 24-hr exposure of a ring-stage culture to 2.5 M CLT suggests that CLT may be potentially effective in relatively short-term treatments.
Given orally, a substantial fraction of CLT is absorbed; it diffuses readily into all tissues and is rapidly metabolized (10, 11) . Absorption is more efficient when given in oil solution than in tablets (12) . Infants and children have shown good absorption and delayed excretion, compared with adults (13) . Pediatric and adult administrations of high doses of CLT (100 mg͞kg per day in four six-hourly oral doses) for treatment of mycotic infections have been well tolerated without significant clinical, hematological, or biochemical side effects (14) . Pharmacokinetic information on CLT in humans indicates that, in healthy subjects after a single oral dose of 1 g CLT (Ϸ15 mg͞kg body weight), plasma levels reach mean peak concentrations of about 2 M within 2-4 hr of administration (15, 16) . Similar and even higher CLT levels have been found by others after oral administration of comparable doses (12, 17) . Most of CLT in plasma is bound to lipoproteins, 4% is bound to albumin, and less than 1% appears to be free (15) . However, CLT partition into red cells in vivo is sufficient to inhibit up to 92% of the intermediate conductance K ϩ (Gardos) channel (16), another CLT target (18) , with an IC 50 of 1 M in whole blood. This finding suggests that binding to plasma proteins is loose and of low affinity relative to targets with micromolar dissociation constants. Intracellular targets with high CLT affinity may thus efficiently extract the drug from plasma components. Moreover, persistence of Gardos channel inhibition after discontinuation of CLT administration, sometimes even when plasma levels had become undetectable (16) , suggests that attention to plasma levels alone may lead to underestimation of the potential effectiveness of CLT in vivo. The short elimination half-life of CLT (Ϸ3 hr) (15) suggests that multiple dosing over a period of four parasite cycles may be necessary for optimal cytotoxic antimalarial effects in vivo (19) .
In contrast with other antifungal agents, development of fungal resistance to CLT has not been observed in vivo (14, 20) and has been extremely difficult to elicit in vitro. Attempts to induce the emergence of fungal mutants with enhanced resistance to CLT, after multiple subcultures, have failed to demonstrate significant changes in the drug's IC 50 in a variety of strains (14) . Whether or not this behavior would apply to malaria parasites remains to be determined. CLT's short elimination time and the steep slope of the concentration-response curve shown here for trophozoites (Fig. 1) are additional features associated with a low probability of development of resistance (21) .
The main aims of combined therapy are to delay development of drug resistance and to find combination partners that potentiate the individual antimalarial effects (21) (22) (23) . The antagonism documented here between CLT and chloroquine indicates that this combination should be avoided. However, further research is required to confirm unequivocally our preliminary results on the synergistic effect between CLT and mefloquine. These results are reminiscent of the interactions between artemisin, or arteether, with chloroquine and mefloquine (24) (25) (26) (27) .
The antimalarial effects of imidazole agents have been known since the early eighties (28) (29) (30) (31) . However, the mechanism of the antimalarial activity of CLT is unknown. CLT has been shown to have a multiplicity of effects on cell proliferation (32) , steroid metabolism (33) (34) (35) , and sickle cell dehydration (36, 37) . The mechanism of these actions has been variously attributed to its inhibitory effect on cytochrome P450-dependent enzymes (38) , sarcoplasmic reticulum Ca 2ϩ pump (39) , capacitative Ca 2ϩ channels (32, 40, 41) , and the intermediate-conductance Gardos channel (18) . The diversity of reported actions suggests that CLT may act independently on a surprising variety of targets. From the effects of CLT in other biological systems a number of possible modes of action may be considered. The fungicidal action, shared with other imidazoles, results mainly from inhibition of cytochrome P450-dependent enzyme systems (38, 42, 43) . Alternative mechanisms shown for other imidazoles have been related to inhibition of catalase and peroxidase activities (44), of potential significance because the malaria parasite is inherently under considerable oxidant stress (45, 46) , and also because various pro-oxidants have been shown to have antimalarial activity (45, 47, 48) . Oxygen enhances the antimalarial activity of some imidazoles; the imidazole drug ketoconazole has a greater antimalarial effect in older red cells, which are more susceptible to oxidative stress, than in younger red cells (31) , effects that may be shared by CLT. The antiproliferative action of CLT results mainly from inhibition of the sarcoplasmic reticulum Ca 2ϩ pump and capacitative Ca 2ϩ channels (32, 39, 49) , which induces depletion of intracellular Ca 2ϩ stores. Store depletion activates protein kinase R, causing phosphorylation of the eukaryotic translation initiation factor 2␣ and inhibition of protein synthesis (49) .
While this work was in progress, Saliba and Kirk (50) reported the effect of CLT on the viability of a P. falciparum strain (FAF6), monitored by measuring the parasite-derived lactate dehydrogenase produced over a 48-hr period. They also showed that the imidazole group plays a significant role in the antimalarial activity of CLT. The IC 50 for the effect of CLT on viability was found to be similar to the IC 50 values reported here for hypoxanthine incorporation. Thus, CLT has been shown to be effective in six different P. falciparum strains, irrespective of their chloroquine sensitivity.
The potent in vitro antimalarial activity of CLT on chloroquine-sensitive and chloroquine-resistant strains of P. falciparum demonstrated here, the lower toxicity of CLT relative to other imidazoles, the failure to develop fungal drug resistance to CLT, the adequate plasma levels obtained after oral administration of the drug, the short elimination time, the high partition in erythrocyte targets, and the proven clinical safety and tolerance in infants and adults suggest that CLT holds much promise as an effective antimalarial agent and new structural lead, and that it is suitable for a pilot clinical study in uncomplicated P. falciparum malaria.
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